Quarterly ResultMay 11, 2026, 04:39 PM
STERIS FY26 Revenue +9% to $5.9B; Adjusted EPS $10.17; $1B Buyback
AI Summary
STERIS plc announced strong financial results for its fiscal 2026 fourth quarter and full year ended March 31, 2026. Full year revenue from continuing operations increased 9% to $5.9 billion, with adjusted diluted EPS rising to $10.17. The company also reported a 7% increase in fourth-quarter revenue to $1.6 billion and a significant increase in free cash flow. Additionally, STERIS's Board of Directors authorized a new $1 billion share repurchase program, replacing the prior authorization.
Key Highlights
- Full year fiscal 2026 revenue from continuing operations increased 9% to $5.9 billion.
- Full year fiscal 2026 adjusted diluted EPS from continuing operations increased to $10.17.
- Q4 fiscal 2026 revenue from continuing operations increased 7% to $1.6 billion.
- Healthcare segment revenue grew 7% to $1.14 billion in Q4, with 6% constant currency organic growth.
- Applied Sterilization Technologies (AST) revenue increased 6% to $289.2 million in Q4.
- Life Sciences revenue increased 9% to $162.9 million in Q4, with 6% constant currency organic growth.
- Net cash provided by operations for fiscal 2026 was $1.34 billion, with free cash flow of $982.9 million.
- Board approved a new $1 billion share repurchase program.
Price Impact
More from STE